AVEO Pharmaceuticals Inc

AVEO Pharmaceuticals — Investor Presentation (August 2022)

44 slides from AVEO Pharmaceuticals's investor presentation, Aug 9, 2022

  1. Slide 1: Corporate Overview August 2022

    Passionately pursuing a better life for patients with cancer Corporate Overview August 2022

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained

  3. Slide 3: Oncology Company With Pipeline to Drive Long-term Growth

    Preclinical Phase 1 Phase 2 Phase 3 Regulatory Filing Marketed Partner VEGFR TKI Ficlatuzumab Anti-HGF/c-MET IgG1 mAb AV-380 Anti-GDF15 IgG1 mAb AV-203 Anti-ERBB3 IgG1 mAb AV-353 Anti-Notch 3 IgG1 mAb Oncology Company With Pipeline to Drive Long-term Growth Ex-US (RCC 1st line) US (RCC following two

  4. Slide 4: Oncology

    ONCOLOGY ()FOTIVDA M/=O (tivozanio) capsules

  5. Slide 5: FOTIVDA (tivozanib)

    Full prescribing information available at www.FOTIVDA.com FOTIVDA® (tivozanib) FOTIVDA (tivozanib) is an oral, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory (R/R) advanced renal cell carcinoma (

  6. Slide 6: FOTIVDA: A Uniquely Positioned VEGF-TKI

    FOTIVDA: A Uniquely Positioned VEGF-TKI • Potent, selective, long half-life inhibitor of all three VEGF receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities • TIVO-3: Superior disease control (PFS, ORR & DoR) vs. sorafenib • Fewer dose reductions, interruptions

  7. Slide 7: ASCO 2022 – Five Year Efficacy Update

    7 ASCO 2022 – 5 Year Efficacy Update • Five year follow-up data show FOTIVDA® (tivozanib) patients were up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib) and a trend toward improved Overall Survival (OS) HR=0.89 • When OS was conditioned on 12 months of PFS, an improv

  8. Slide 8: Significant Unmet Need In R/R Advanced RCC

    Significant Unmet Need In R/R Advanced RCC1 Limited data exists for the treatment of highly refractory RCC patients and following immunotherapy Existing treatment options have tolerability challenges requiring frequent dose modifications Only about 50% of patients who received second-line treatment

  9. Slide 9: IMDC Database: Third-line Treatment Demonstrated to Improve Survival

    0.00 0.25 0.50 0.75 1.00 0 20 40 60 80 100 IMDC Database: Third-line Treatment Demonstrated to Improve Survival ~2X vs. No Therapy1 9 ** 1 Wells JC, et al. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consorti

  10. Slide 10: US RCC Market by Line of Therapy

    US RCC Market by Line of Therapy 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 18,000 1st Line 2nd Line 3rd Line+ Annual Incidence of RCC Patients by Line of Therapy1 Treated Un-Treated 1) Decision Resources Group (DRG) projections 2022 (Nov. 2021 Market Update) • 10,000 patients make it to

  11. Slide 11: Quarter over Quarter Prescription Growth

    0 283 619 780 977 1,157 Q1 '21* Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 T o ta l P re s c ri p ti o n V o lu m e Quarter over Quarter Prescription Growth Q2 ‘22 Notes • 18% growth in TRxs from Q1 ’22 to Q2 ’22 • 309% growth in TRxs over Q2 ’21 • Increasing in-person access and activity *Commercial Availa

  12. Slide 12: FOTIVDA U.S. Net Product Revenue by Quarter

    FOTIVDA® U.S. Net Product Revenue by Quarter $6.7 $14.3 $16.8 $20.1 $25.0 Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 (I n M il li o n s ) Q2 ‘22 Notes • 24% growth in U.S. Net Product Revenue from Q1 ’22 to Q2 ’22 • 271% growth in U.S. Net Product Revenue over Q2 ’21 • Reaffirm guidance of $100-110m in ’22

  13. Slide 13: Impact of NCCN Guideline Update on Decision Making

    Nearly 80% of respondents indicated that the recent NCCN Guideline update elevating tivozanib to a Category 1 recommendation was significantly or moderately impactful on their treatment decisions, in a recent third party market research survey 9% 12% 40% 39% 0 20 40 60 80 100 No impact Low impact Mo

  14. Slide 14: Improving 3rd Line+ Duration of Therapy

    Improving 3rd Line+ Duration of Therapy • Longitudinal data available for approximately 250 real world patients initiating treatment in Q2 through Q4 2021 (Minimum of 6 months follow up) • Average duration is currently 4.7 months with 21% continuing active treatment 0 1 2 3 4 5 21% Still Ongoing Lon

  15. Slide 15: Focused Oncology Team with Broad Market Coverage

    Focused Oncology Team with Broad Market Coverage • Experienced oncology field force for effective market coverage (~65 FTEs) • Commercial Team designed for success through evolving COVID restrictions • Full in-person and remote customer engage capabilities • Multi-channel promotional initiatives • A

  16. Slide 16: Best-in-Class Patient Access Services

    Best-in-Class Patient Access Services • FOTIVDA® (tivozanib) Is Available Through a Limited Network of Specialty Pharmacies and Distributors • Limited distribution model through high-touch specialty pharmacies and top specialty distributors supports in-office dispensing practices. • Unique model in

  17. Slide 17: FOTIVDA Recognized As Overperforming First Launch

    FOTIVDA Recognized As Overperforming First Launch *https://www.zs.com/insights/us-emerging-pharma-biotech-first-launch-analysis

  18. Slide 18: Tivozanib Combination Opportunities

    Tivozanib Combination Opportunities

  19. Slide 19: Tivozanib Properties May Provide Unique Advantages in Combination with CPI Therapy

    Nakamura K et al. Cancer Res 2006;66:9134–9142. Pawlowski N et al. AACR 2013. Poster 3971. Hammers, Emerging VEGF-I/O Combinations, ASCO 2017 Tivozanib Properties May Provide Unique Advantages in Combination with CPI Therapy 19 Tolerability is Important in Combinations Tivozanib Significantly Reduce

  20. Slide 20: Anti-tumor Activity Seen in Treatment Naive and Previously Treated RCC Patients

    Treatment Naïve (n=12) Pre-Treated (n=13) Includes 2 Prior CPI Pts Overall (n=25) CR 8% - 4% PR 42% 62% 52% ORR (CR+PR) 50% 62% 56% DCR (CR+PR+SD) 92% 100% 96% mPFS 18.9 mo (4.7, NR) NR* (11.0, NR) 18.9 mo (16.4, NR) Dose reductions 17% Nivolumab Mono2Tivozanib Mono1 ORR 18% PFS 11.0 ORR 25% PFS 4.6

  21. Slide 21: TiNivo-2: Pivotal Trial in RCC Following Prior Immunotherapy

    TiNivo-2: Pivotal Trial in RCC Following Prior Immunotherapy Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare FOTIVDA® with OPDIVO® to FOTIVDA® in RCC Patients Following One or Two Lines of Therapy, One of which was an Immune Checkpoint Inhibitor N = 326 • Histologically /

  22. Slide 22: 1st Line HCC VEGF Combination Comparison

    Regimen Study PS Status ECOG 0 ORR^ DCR PFS* 1 Year OS Rate Bev+Atezo1, 2 Ph3 N=501 (2:1) 62% 28% 74% 6.8m 67% Cabo+Atezo3 Ph3 N=372 (2:1) 64% 11% 78% 5.8m N/A Tivo+Durva4 Ph2 N=18 40% 28% 72% 7.3m 76% References: 1USPI for Tecentriq; 2Verret, W. et al., Atezolizumab plus Bevacizumab in Unresectable

  23. Slide 23: Clinical Trial Collaboration: Tivozanib and NKT2152

    Clinical Trial Collaboration: Tivozanib and NKT2152 • AVEO and NiKang entered into a clinical trial collaboration and supply agreement to evaluate NKT2152, NiKang’s small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with tivozanib • Sixty patient Phase 2 clinical trial

  24. Slide 24: Ficlatuzumab Anti-HGF/c-MET IgG1 mAb

    Ficlatuzumab Anti-HGF/c-MET IgG1 mAb

  25. Slide 25: Scientific Rationale for Ficlatuzumab in Combination with Cetuximab for HPV-negative HNSCC

    Scientific Rationale for Ficlatuzumab in Combination with Cetuximab for HPV-negative HNSCC 25 Source: Zhang Y, Jain R and Zhu M. Biomedicines, 2015 (Zhang Y, Jain RK, and Zhu M. Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment. Biomedicines. 2015; 3, 149-181 d

  26. Slide 26: Potential Ficlatuzumab Registrational Trial in HPV Negative HNSCC

    Potential Ficlatuzumab Registrational Trial in HPV Negative HNSCC Update • Granted U.S. FDA Fast Track Designation for the treatment of patients with R/R HNSCC • Completed drug substance manufacturing for potential registrational study of ficlatuzumab in 2Q 2022 • Potential registrational trial star

  27. Slide 27: Financials and Near-Term Milestones

    Financials and Near-Term Milestones

  28. Slide 28: Financial Snapshot as of June 30, 2022

    28 Cash as of June 30, 2022 $77.2M Total U.S. Net Product Revenue 2Q 2022 $25.0M Debt as of June 30, 2022 $38.4M Shares Outstanding as of June 30, 2022 34.6M 2Q 2022 1H 2022 Cash Burn from Operations ($1.9M) ($10.2M) AVEO believes that its current cash, cash equivalents and marketable securities, al

  29. Slide 29: Key Recent and Potential Milestones

    Key Recent and Potential Milestones AV-380 (Anti-GDF15 IgG1 mAb) 2021 1H 22 2H 22 Initiate Phase 1b Trial in Cancer Patients with Elevated GDF15 Levels Who Have the Potential to Develop Cachexia Ficlatuzumab (Anti-HGF/c-MET IgG1 mAb) 2021 1H 22 2H 22 HNSCC Randomized (Ficlatuzumab +/- Cetuximab) Pha

  30. Slide 30: Thank you

    Passionately pursuing a better life for patients with cancer Thank you

  31. Slide 31: Appendix

    Appendix A/=O ONCOLOGY

  32. Slide 32: FOTIVDA: A Differentiated VEGFR 1, 2 and 3 TKI

    FOTIVDA: A Differentiated VEGFR 1, 2 and 3 TKI Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life designed to improve efficacy and tolerability 32 Pawlowski N et al. AACR 2013. Poster 3971. • Cabozantinib and lenvatinib are not shown because absolute oral bioavailabilities are no

  33. Slide 33: TIVO-3: Pivotal Trial in RCC

    : Pivotal Trial in RCC Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib to Sorafenib in Subjects With R/R Advanced RCC Results published in Lancet Oncology in December 2019 N = 350 • Histologically / cytologically confirmed recurrent/metastatic RCC • ECOG PS 0 or

  34. Slide 34: TIVO-3: First Positive Phase 3 Dataset in Adult Patients Receiving Two or More Prior Systemic Therapies

    : First Positive Phase 3 Dataset in Adult Patients Receiving Two or More Prior Systemic Therapies Source: PFS final analysis, Oct 4, 2018, U.S. FOTIVDA® Package Insert34 TIVO-3 Primary Endpoint: PFS of Tivozanib vs. Sorafenib Secondary Endpoints: ORR, DCR, DoR, OS Treatment Group Tivozanib n=175 Sor

  35. Slide 35: TIVO-3: Exploratory Analysis of Pre-Defined Subgroups

    : Exploratory Analysis of Pre-Defined Subgroups: Prior Checkpoint Inhibitor and TKI/TKI 35 Porta et al. ASCO 2019 Other + VEGFR TKI: (N=100) HR=0.98; 95% CI 0.62; 1.56, ASCO GI 2019 0 20 40 60 80 100 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 P ro g re s s io n -f re e S u rv iv a l (% ) 0 20 40 60

  36. Slide 36: TIVO-3: Safety & Tolerability

    *Analysis as of Aug 15, 2019; ^Safety population **Includes fatigue and asthenia; † Includes hypertension, blood pressure increased, hypertensive crisis; § Includes diarrhea and frequent bowel movements.; # Includes dermatitis, dermatitis acneiform, dermatitis contact, drug eruption, eczema, eczema

  37. Slide 37: Ficlatuzumab Anti-HGF/c-MET IgG1 mAb

    Ficlatuzumab Anti-HGF/c-MET IgG1 mAb

  38. Slide 38: Ficlatuzumab: Phase 2 Randomized Study in Pan-Refractory, Metastatic HNSCC Patients

    Ficlatuzumab: Phase 2 Randomized Study in Pan- Refractory, Metastatic HNSCC Patients Randomized, confirmatory Phase 2 study in combination with cetuximab, an EGFR-targeted antibody, patients who relapsed or were refractory to prior immunotherapy, chemotherapy, and cetuximab with metastatic HNSCC N =

  39. Slide 39: Efficacy Benchmarks: Low Response Rates and Limited PFS in R/M HNSCC

    FDA Approved Nov 20162,3 Ph3 n=361 OPDIVO (nivolumab) vs Investigator Choice ORR 13% vs 5.8% 2.0m vs 2.3m PFS 1ERBITUX (cetuximab) USPI November 2020, Eli Lilly and Company, Indianapolis, IN. 2OPDIVO (nivolumab) USPI January 2021, Bristol Myers Squibb, Princeton, NJ., 3http://www.fda.gov/Drugs/Infor

  40. Slide 40: Significant Unmet Need Exists for HPV Negative HNSCC

    Significant Unmet Need Exists for HPV Negative HNSCC1 40 1 Galvis et al, Critical Reviews in Oncology/Hematology 15 (2020) 102966

  41. Slide 41: Ficlatuzumab Plus Cetuximab Improved Outcomes in HPV Negative HNSCC

    41 Ficlatuzumab Plus Cetuximab Improved Outcomes in HPV Negative Pan-Refractory, Metastatic HNSCC HPV negative HNSCC is historically associated with poorer outcomes compared to HPV positive disease F (=26) F+C (n=32) HPV+ ORRa 0/10 (0%) 0/16 (0%)d mPFSb NEc 2.3 (1.9)e HPV- ORRa 1PR/16 (6%) 2CR + 4PR

  42. Slide 42: Additional Pipeline Programs

    Additional Pipeline Programs

  43. Slide 43: AV-380: GDF15 Role in Cachexia

    AV-380: GDF15 Role in Cachexia 43 * J. Cachexia, Sarcopenia and Muscle 2010 + AVEO data on file Cachexia is a muscle wasting disease commonly associated with cancer • ~50% of people with cancer will suffer from cachexia* • ~30% of all cancer patients die from cachexia* GDF15 is a key driver in cance

  44. Slide 44: AV-203: A potent humanized IgG1 mAb that targets ErbB3

    AV-203: A potent humanized IgG1 mAb that targets ErbB3 • Humanized IgG1 antibody – Low risk of ADA response and hypersensitivity – Potential for inducing ADCC • Potent inhibitor of NRG/HRG - dependent and independent ERBB3 activation • Higher ERBB3 affinity and more potent anti-tumor activity than c

AVEO Pharmaceuticals — Investor Presentation (August 2022) on 6ix